DEPRENYL COMPOUNDS TO TREAT VIRAL INFECTIONS AND REDUCE TISSUE DAMAGE ASSOCIATED THEREWITH

• US 20020137786A1
• Filed: 02/11/1999
• Published: 09/26/2002
• Est. Priority Date: 02/12/1998
• Status: Abandoned Application

• Current Assignee: Katherine L.B. Borden, Maria Salvato, William G. Tatton
• Original Assignee: Katherine L.B. Borden, Maria Salvato, William G. Tatton
• Inventors: SALVATO, MARIA, BORDEN, KATHERINE L. B., TATTON, WILLIAM G.
• Application Number:
  US09/249,350
• Publication Number:
  US 20020137786A1
• Time in Patent Office: Days
• US Class Current: 514/408
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/35 having six-membered rings with one oxygen as the only ring hetero atom
• CPC Class Codes: A61K 31/40 having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Methods for treating viral infections are disclosed. The methods of the invention are useful for inhibiting viral infection in a subject and for preventing reducing tissue damage associated with viral infections. The method can include the step of administering to a subject in need thereof a therapeutically effective amount of a deprenyl compound, such that treatment of a viral infection occurs.

Claims

1. A method of treating a viral infection, comprising administering to a subject in need thereof a therapeutically effective amount of a deprenyl compound, such that treatment of the viral infection occurs.

2. The method of claim 1, wherein the viral infection is caused by an RNA virus.

3. The method of claim 2, wherein said RNA virus is selected from the group consisting of HIV, Herpes Simplex-1 virus, hepatitis A virus, Epstein-Barr virus, SV-40 virus, cytomeglavirus and adenovirus-5.

4. The method of claim 1, wherein the deprenyl compound is represented by the formula:

5. The method of claim 1, wherein the deprenyl compound is (−

)-desmethyldeprenyl.

6. The method of claim 1, wherein the deprenyl compound is administered to the subject by transdermal administration.

7. The method of claim 1, wherein the deprenyl compound is administered in a pharmaceutically acceptable carrier.

8. The method of claim 1, wherein the subject is a human.

9. A method of inhibiting replication of a virus in a virus-infected cell, comprising contacting the virus-infected cell with an effective amount of a deprenyl compound, such that the affinity of GAPDH for viral RNA is decreased and viral replication in the virus-infected cell is inhibited.

10. The method of claim 9, wherein the virus is selected from the group consisting of HIV, Herpes Simplex-1 virus, hepatitis A virus, Epstein-Barr virus, SV-40 virus, cytomeglavirus and adenovirus-5.

11. The method of claim 9, wherein the virus-infected cell is a cell in cell culture.

12. The method of claim 9, wherein the deprenyl compound is represented by the formula:

13. The method of claim 12, wherein the deprenyl compound is (−

)-desmethyldeprenyl.

15. The method of claim 14, wherein the deprenyl compound associates with GAPDH such that the conformation of GAPDH is altered.

16. The method of claim 14, wherein the deprenyl compound is represented by the formula:

17. The method of claim 16, wherein the deprenyl compound is (−

)-desmethyldeprenyl.

19. The method of claim 18, wherein the colocalization of GAPDH with PML is inhibited by contacting GAPDH with a depreneyl compound.

14. A method for decreasing the affinity of GAPDH for viral RNA, the method comprising contacting GAPDH with a deprenyl compound, such that the affinity of GAPDH for viral RNA is decreased.

18. A method for inhibiting replication of a virus in a virus-infected cell, comprising inhibiting colocalization of GAPDH with PML such that replication of the virus in the virus-infected cell is inhibited.

20. A method for inhibiting tissue damage due to viral infection, comprising administering to a subject in need thereof an effective amount of a deprenyl compound such that prevention of tissue damage due to viral infection occurs.

21. The method of claim 20, wherein said viral infection is selected from the group consisting of HIV, Herpes Simplex-1 virus, hepatitis A virus, Epstein-Barr virus, SV-40 virus, cytomeglavirus and adenovirus-5.

22. The method of claim 20, wherein the deprenyl compound is represented by the formula:

23. The method of claim 22, wherein the deprenyl compound is (−

)-desmethyldeprenyl.